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Abstract
Recurrent Clostridium difﬁcile infections constitute an important medical concern. Evidence has been provided showing that faecal microbiota
transplantation is a more efﬁcient treatment than antibiotics. Serious side effects are unusual, and acceptability is not an obstacle.
Nevertheless, protocols are heterogeneous with respect to the selection of donors and the methodology used for the faecal
transplantation. Regulations by both the Food and Drug Administration and the French authorities consider stool samples to be drugs, and
suggest strict supervision in clinical trials. Donor screening by questionnaire or by blood and stool analysis, which is essential in eliminating
pathogens or viruses before transplantation, is similar in different countries, with a few exceptions. The traceability of the faecal transplant
and long-term follow-up of the patients in clinical trials are issues that may be difﬁcult to organize. The use of frozen microbiota facilitates
transplantation, and the nasogastric route seems to be at least as effective as other invasive methods and avoids the risk of anaesthesia.
Synthetic microbiota is an approach that selects a mixture of bacteria, thereby eliminating the risk of transmissible disease; however, this
approach is not yet evidence-based. The use of pills, which is currently being tested in clinical trials, will certainly be the starting point for the
extensive use and wide industrialization of faecal microbiota transplantation.
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Introduction
Clostridium difﬁcile infection (CDI) is the primary cause of
healthcare-associated diarrhoea, with worldwide outbreaks
caused by diverse ribotypes [1,2]. The mortality rate ranges
from 5% to more than 40%, depending on the strains and
clinical status of the host [1,3–6]. For example, the Centers for
Disease Control and Prevention estimated that CDI causes
14 000 deaths annually in the USA. Despite antibiotic treat-
ment with metronidazole, vancomycin, or ﬁdaxomicin, the
relapse rate is still up to 35% [7]. Faecal microbiota
transplantation (FMT) was ﬁrst proposed empirically in 1958
as a method of treating CDIs [8], and cases series using FMT as
a treatment for recurrent infections were reported [9]. FMT
has recently been shown to be clearly superior to antibiotics in
a randomized clinical study [10]. Indeed, in 2013, Van Nood
et al. [10] demonstrated better efﬁcacy of FMT than of the
conventional treatment with vancomycin in patients with
recurrent CDI. Among the 16 patients treated with faeces
infusion, none had severe adverse events. Most of the patients
had their diarrhoea resolved within 3 h after infusion, and 19%
had constipation. Recently, the European Society of Clinical
Microbiology and Infectious Diseases strongly recommended
the use of FMT in patients with several relapses [11]. The
cost-effectiveness of FMT colonoscopy for the management of
recurrent CDI was recently demonstrated to be superior to
that of the usual antibiotics [12]. Additionally, a recent study
demonstrated the efﬁciency of FMT in recurrent CDI, even in
strongly immunocompromised patients, who had initially
represented a limited indication [13]. Finally, some scientists
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have proposed the use of FMT in other clinical conditions, such
as inﬂammatory bowel diseases, although the results are less
encouraging than those obtained for recurrent CDIs [14–16].
Consequently, this alternative and efﬁcient treatment needs
regulation and standardization (Fig. 1). However, no consen-
sus exists regarding health safety, legislative aspects, donor
screening, and the administration route. We herein provide a
review regarding these aspects, which will require standard-
ization before the probable wide-scale industrialization
because of the promising number of indications.
Regulation Aspects
Health authorities have been alerted to the absence of faecal
transplant status and regulations, given the accumulating
evidence showing the effectiveness of such treatments [10].
In France and the USA, authorities have considered FMT to be
a drug, in contrast to the UK, Denmark, and The Netherlands.
We can also observed the difﬁculties of authorities, shared
between the high pressure from patients and clinical doctors
performing FMT, and the necessary regulations [17].
Indeed, in the USA, the US Food and Drug Administration
(FDA) stated in the autumn of 2012 that human faeces
constituted a drug (http://www.fda.gov/downloads/Biologics-
BloodVaccines/GuidanceComplianceRegulatoryInformation/
Guidances/Vaccines/UCM361393.pdf) [18]. This had the unin-
tended consequence of putting faeces used for FMT under the
jurisdiction of hospital pharmacies, requiring storage of the
faecal product in the pharmacy [18]. In addition, a time-
consuming investigational new drug (IND) status was ﬁrst
proposed for the conduct of studies in humans [19]. The
objectives were to improve the safety of and standardize the
use of FMT [17]. The FDA noted that the efﬁcacy and safety
proﬁles of this intervention had not yet been fully evaluated in
controlled clinical trials, and organized a public workshop to
provide a forum for the exchange of experiences among the
medical and scientiﬁc community about the regulatory issues
associated with FMT. After this public meeting and several
opinions of different authorities, 6 weeks later, the FDA’s
guidance documents stated that this protocol including an IND
status was suggested or recommended but not required
[17,19]. Indeed, the FDA proposed a compassionate exception
to allow the many people suffering from CDI to beneﬁt from
the use of FMT. The FDA recommended that the treating
physician obtain adequate informed consent from the patient
or his or her legally authorized representative for the use of
FMT. Informed consent should include, at a minimum, a
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FIG. 1. Scientiﬁc and regulatory key events from 1858 to 2014 in faecal microbiota transplantation. We found an increasing number of citations by
using the ISI web of knowledge and ‘fecal microbiota transplantation’ as the keyword. CDI, Clostridium difﬁcile infection.
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statement that the use of FMT products to treat CDI is
investigational and a discussion of its potential risks. The FDA
proposed this on an interim basis while the agency develops
appropriate policies for the use of FMT as an IND.
In France, in March 2014, the National Security Drugs
Agency (Agence Nationale pour la Securite du Medicament)
also considered FMT to be a drug (http://ansm.sante.fr/var/
ansm_site/storage/original/application/5e5e010183037901942
75ded0e02353c.pdf). In the absence of market authorization,
the National French Agency recommended that FMT must
have the same legislative framework as experimental drugs or
magisterial preparations. Indeed, the preparation was under
the responsibility of the hospital pharmacist. The authorities
strongly recommended supervising the use of FMT in clinical
trials, but left open the possibility of clinicians performing FMT
with compliance with stringent recommendations [20]. They
also recommended stringent screening of the donors, asking
the clinicians to determine the reasons for non-compliance
with the protocol. Finally, in the UK, in March 2014, the UK
National Institute for Health and Care Excellence (IPG 485)
deemed FMT to be a safe and effective treatment for recurrent
CDI (http://www.nice.org.uk/guidance/IPG485) [21].
Overall, to date, most countries have proposed strict
requirements to limit the practice of FMT for recurrent CDI.
Nonetheless, differences regarding the ‘drug’ or ‘tissue’ status
remain. For example, the FDA deﬁnes drugs as ‘articles
intended for use in the diagnosis, cure, mitigation, treatment,
or prevention of disease’ [17]. Faecal microbiota is a variable
and complex ecosystem composed of a mixture of microor-
ganisms, metabolites, and human cells [17,19,22]. As has been
the case for semen, which is a tissue product, and blood, which
has its own rules, a special status for FMT may be useful,
because it is very difﬁcult to characterize faecal samples
according to the rigorous standards applied to conventional
drugs. We must ﬁnd the balance between stringent rules to
protect human health and rules that are too restrictive, and
that may lead patients to consider unregulated and expensive
proposals that are available on the Internet or, worse,
home-made protocols that are available on YouTube [17].
How do we Preserve the Health and Safety
of Patients Treated with FMT?
The recruitment and screening of donors is a lengthy process
that is essential to ensure the health and safety of patients.
Patient selection
Most of the clinical studies and the authority recommendations
that have been suggested to date exclude immunocompromised
patients, who have a high risk of developing CDI, pregnant
women, and patients treated with antibiotics for reasons other
than forCDIon thedayof inclusion.Nevertheless, a recent study
that included human immunodeﬁciency virus (HIV) patients,
solid organ transplant patients and patients with immunosup-
pressive therapy for inﬂammatory bowel disease obtained an
overall cure rate of 89%, without related infectious complica-
tions, in these high-risk patients. These results should signiﬁ-
cantly and rapidly affect the current recommendations [13,23].
Donor screening
Clinical examination. For example, the National French Agency
proposes a two-step selection process. The ﬁrst visit consists
of a pre-inclusion screening with questioning, a clinical
examination, and a biological examination. Donors younger
than 18 years with a history of Salmonella Typhi infection,
chronic diseases or long-term treatment (without precision),
diarrhoea within the past 3 months, or overseas travel within
the past 3 months, and donors who had been hospitalized, or
whose family members had been hospitalized, within the past
12 months, were systematically excluded. In addition, the
French authorities recommend avoiding donors who are aged
>65 years or have a body mass index of >30, donors treated
with antibiotics within the past 3 months, or donors with a
familial history of autoimmune diseases, inﬂammatory bowel
diseases, or colorectal neoplasms. The second visit for
consideration consists of a supplementary questionnaire to
detect criteria for non-inclusion that may have occurred since
the inclusion visit (e.g. diarrhoea, travel, human blood expo-
sure, and sexual exposure to risk) [20].
Biological screening: faecal samples
Van Nood recommended performing both bacteriological and
parasitological evaluations and testing for the presence of
C. difﬁcile (toxin ELISA and culture) [10]. The French author-
ities proposed extremely detailed recommendations that
included the detection of a comprehensive list of pathogens:
C. difﬁcile, Listeria monocytogenes, Vibrio cholerae, Vibrio parahae-
molyticus, Salmonella species, Shigella species, adenoviruses,
astroviruses, caliciviruses, picornaviruses, rotavirus, and hep-
atitis A and E viruses. Regarding parasitic infections, they
recommended testing for the presence of Strongyloides sterco-
ralis, Cryptosporidium species, Cyclospora species, Entamoeaba
histolytica, Giardia intestinalis, Isospora species and microsporidia.
The National French Agency also strongly recommends testing
for the carriage of extended-spectrum b-lactamase-producing
enterobacteria in the donors [20,24].
Biological screening: blood samples. Van Nood [10] proposed
testing for active infections caused by cytomegalovirus,
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Epstein–Barr virus, hepatitis A virus, hepatitis B virus, HIV-1,
HIV-2, human T-lymphotropic virus types I and II, Treponema
pallidum, E. histolytica, and S. stercoralis. In addition, the French
authorities recommend testing for Toxoplasma gondii and
Trichinella species [20].
Adverse outcome follow-up
Smits et al. [15], who have a large amount of experience with
FMT, reported no serious side effects. Van Nood [10]
reported diarrhoea or abdominal pain, which disappeared a
few hours after the procedure. In a recent study by Kelly
et al. [13], one patient died of aspiration during sedation for
FMT administered via a colonoscopy. Overall, transient
abdominal discomfort, diarrhoea, constipation and bloating
have been the most frequently described side effects.
Nevertheless, very few long-term follow-up data are available
in the literature [17]. Additionally, the theoretical risk that
FMT could modify the microbiota of the patients and make
them susceptible to chronic conditions such as obesity or
autoimmune disorders [17] encourages the establishment of
mandatory registries to protect against infectious diseases
and to track adverse events, including long-term adverse
events, as required by the FDA and the French authorities
[17,20]. Considering the efﬁcacy of FMT for the treatment of
recurrent CDI performed in a large number of patients
[25,26], the beneﬁt/risk ratio is clearly in favour of this
procedure (Table 1).
How do we Choose the Donor?
To the best of our knowledge, there is no scientiﬁc argument
to recommend anonymous donation rather than directed
donation. Similarly, transplants with pooled faecal material are
comparable with transplants from unique donors in both their
safety and efﬁcacy.
Ethics and acceptability
The strong evidence for the efﬁcacy of FMT in the treatment
of recurrent CDI leads to the question, ‘Is it ethical to not be
able to propose FMT to all patients suffering from recurrent
CDI?’ rather than the question, ‘Is it ethical to propose FMT
for the treatment of recurrent CDI?’
Brandt et al. [27] demonstrated that 73% of patients treated
with FMT would undergo the treatment again, and that 53%
would prefer FMT as the initial therapy in instances of
recurrent CDI. Zipursky et al. assessed patients’ perceptions
regarding the management of CDI by proposing diverse
scenarios. After patients had been informed of the cure rate
percentages for various treatments, most of the patients chose
FMT for treatment, but they did not know the nature of the
treatment. Only 16 individuals changed their choices when the
authors explained what FMT actually was [7]. The authors
noted that the acceptability was higher when the clinician
recommended this alternative. Finally, the media’s attraction
to a treatment regimen that is easy to sensationalize has
increased its acceptability [17].
How do we Facilitate FMT and Consider
Industrialization?
Frozen faeces and faecal banks
The main limitation of transplantation with fresh faeces was
overcome by the use of frozen faeces; this avoids the need to
maintain an available pool of donors, and allows for the
establishment of a bank of preprocessed material that is rapidly
usable [28]. In 2012, Hamilton et al. [29] proposed moving
from patient-identiﬁed individual donors to standard volunteer
donors, and recently Youngster et al. [28] demonstrated that
transplantation with frozen faeces was effective. Faecal banks
have been established, such as OpenBiome, a company based
in Cambridge, which is a non-proﬁt organization that was
TABLE 1. Summary of the beneﬁt/risk ratio of faecal transplantation for the treatment of recurrent Clostridium difﬁcile infection
and inﬂammatory bowel diseases
Type of study and indication
No. of
patients Beneﬁt Risk
Outstanding safety
questions Reference
Recurrent C. difﬁcile infection – – – Long-term adverse event –
Risk of anaesthesia depends
on the route of administration
Randomized study using the
duodenal route
16 81% cure after one infusion,
93% overall
No severe adverse event – Van Nood et al. [10]
Diarrhoea (94%)
Constipation (19%)
Review 536 87% resolution of diarrhoea No severe adverse event – Cammarota et al. [25]
Review 317 92% resolution of diarrhoea One upper gastrointestinal
haemorrhage
– Gough et al. [9]
Inﬂammatory bowel disease
Review 26 76% reduction of symptoms One activation of Crohn’s
disease
Long-term outcome Anderson et al. [26]
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funded in 2012 to provide faecal transplants for different
hospitals (OpenBiome 2014, http://www.openbiome.org/). The
samples were homogenized, and frozen for long-term storage
[17]. Usually, the faecal solution is poured through a clean
metal sieve in order to remove the food-derived debris [10].
Nevertheless, the FDA recently decided to allow FMT only
when the source of faeces is known to either the physician or
the patient [30], consequently creating difﬁculties for organi-
zations such as OpenBiome in the USA [30]. In addition, two
teaching hospitals, including the Massachusetts General Hos-
pital in Boston and the Emory University Hospital in Atlanta,
developed their own faecal banks for their patients [17]
following the FDA recommendations.
Route of administration
Retention enema was the only route available until 1989 [31].
Since then, alternative methods using colonoscopy, duodenal
tubes or nasogastric tubes have been established [28,31].
Recently, despite difﬁculties in comparing protocols, owing to
unavailable data and differences regarding the quantity of the
transplant, a review concluded that an enema or the colonos-
copy route were probably the most effective protocols. The
only randomized clinical trial demonstrating the efﬁciency of
FMT in recurrent CDI used the duodenal route with
gastroscopy [10]. Finally, a recent study comparing colono-
scopic administration and nasogastric tube administration
demonstrated better efﬁcacy of the upper route [29]. This
mode of administration remains the easiest and the least
invasive, thereby avoiding the risk inherent in general anaes-
thesia.
Synthetic microbiota
Knowledge regarding the gut microbiota composition has been
increased by the use of next-generation sequencing, which has
led researchers to suggest links between diseases and the
bacterial community at the genus or species level [31–34]. The
next step could be using this association to improve human
health by designing an ideal microbiota [17]. Preliminary
studies have been designed in mice or in patients with CDI
[35]. For example, Jorup-Ronstrom et al. [36] used subcul-
tured human donor microbiota, obtaining a success rate of
69%, and Petrof et al. [37] used 33 isolates of bacterial species
cultured from the human gut of one donor to demonstrate
efﬁcacy in two patients with infections caused by the virulent
ribotype O78. The cocktail was composed of Lactobacillus
species, Escherichia coli, Raoultella species, Biﬁdobacterium
species, Clostridium species, and other anaerobic bacterial
species. Different companies in the USA have already tested
synthetic approaches [17]. The advantages of synthetic
microbiota include avoiding the risks of pathogens and viruses
that are inherent to the use of stool samples, and the
reproducibility of manufacture, which facilitates industrializa-
tion [35].
Nonetheless, treatments with synthetic communities will
not be available for many years. Currently, to the best of our
knowledge, except case series, there is no evidence of
comparable efﬁciency, than transplantation using stool sam-
ples. In addition, caution should be recommended because
we know the differences in the composition of the gut
microbiota depends of the tools used to explore the
microbiota [38,39].
Pills
FMT, which allows for the recovery of the gut microbiota [40]
to cure recurrent CDI, is a method that remains limited to a
few hospital centres. To the best of our knowledge, no human
clinical studies have been published to date regarding the use
of lyophilized, encapsulated and enteric-coated capsules for
oral administration. Nevertheless, clinical trials with stool-der-
ived pills are ongoing (http://clinicaltrials.gov/show/NCT
01914731; http://www.idweek.org/pr-2013-cdiff/) [30,41,42].
The development of pills containing microbiota, based on the
model of Saccharomyces boulardii pills, which have been used
for >80 years [43], is likely to accelerate. Ultimately, it is
conceivable that, after any use of antibiotics in patients aged
>65 years, oral FMT will become a routine procedure to
ecologically conserve the gut microbiota.
Conclusion
The efﬁcacy of FMT has now been strongly demonstrated in
recurrent CDI [10]. Other indications, such as the decontam-
ination of patient carriers of extended-spectrum b-lactamase
producers, could be proposed to expand the ﬁeld of interest
for industry [44]. Over six clinical trials studying FMT in
inﬂammatory bowel diseases have also been registered [17].
The standardization of the stringent screening of donors and
follow-up will increase the health and safety of the patients.
Currently, recent data recommending the nasogastric route
and the use of frozen faeces should be applied to facilitate
manipulations and to avoid the risk of anaesthesia [29]. Finally,
in the near future, the use of pills with a possibly standardized
microbiota will be the ﬁnal step before widening the indica-
tions and acceptability of FMT.
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